dc.contributor.author | Parkes, EE | |
dc.contributor.author | Humphries, MP | |
dc.contributor.author | Gilmore, E | |
dc.contributor.author | Sidi, FA | |
dc.contributor.author | Bingham, V | |
dc.contributor.author | Phyu, SM | |
dc.contributor.author | Craig, S | |
dc.contributor.author | Graham, C | |
dc.contributor.author | Miller, J | |
dc.contributor.author | Griffin, D | |
dc.contributor.author | Salto-Tellez, M | |
dc.contributor.author | Madden, SF | |
dc.contributor.author | Kennedy, RD | |
dc.contributor.author | Bakhoum, SF | |
dc.contributor.author | McQuaid, S | |
dc.contributor.author | Buckley, NE | |
dc.date.accessioned | 2021-07-26T08:19:35Z | |
dc.date.available | 2021-07-26T08:19:35Z | |
dc.date.issued | 2021-06-25 | |
dc.identifier.citation | NPJ breast cancer, 2021, 7 (1), pp. 81 - ? | |
dc.identifier.issn | 2374-4677 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4689 | |
dc.identifier.eissn | 2374-4677 | |
dc.identifier.doi | 10.1038/s41523-021-00283-z | |
dc.description.abstract | STING signaling in cancer is a crucial component of response to immunotherapy and other anti-cancer treatments. Currently, there is no robust method of measuring STING activation in cancer. Here, we describe an immunohistochemistry-based assay with digital pathology assessment of STING in tumor cells. Using this novel approach in estrogen receptor-positive (ER+) and ER- breast cancer, we identify perinuclear-localized expression of STING (pnSTING) in ER+ cases as an independent predictor of good prognosis, associated with immune cell infiltration and upregulation of immune checkpoints. Tumors with low pnSTING are immunosuppressed with increased infiltration of "M2"-polarized macrophages. In ER- disease, pnSTING does not appear to have a significant prognostic role with STING uncoupled from interferon responses. Importantly, a gene signature defining low pnSTING expression is predictive of poor prognosis in independent ER+ datasets. Low pnSTING is associated with chromosomal instability, MYC amplification and mTOR signaling, suggesting novel therapeutic approaches for this subgroup. | |
dc.format | Electronic | |
dc.format.extent | 81 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE RESEARCH | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | The clinical and molecular significance associated with STING signaling in breast cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-05-27 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/s41523-021-00283-z | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2021-06-25 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | NPJ breast cancer | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Integrated Pathology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Integrated Pathology | |
pubs.publication-status | Published | |
pubs.volume | 7 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Integrated Pathology | |
icr.researchteam | Integrated Pathology | |
dc.contributor.icrauthor | Salto-Tellez, Manuel | |